Want to see GB:SYNC full AI Analyst Report?
Top Page
Syncona Shs GBP
(LSE:SYNC)
Select Model
Select Model
Rating:52Neutral
Price Target:
129.00 p
▲(20.56% Upside)
Action:Reiterated
Date:09/19/26
The score is held back primarily by volatile and currently loss-making financial performance (including weaker FY2026 revenue and free cash flow falling to zero), partially offset by a very conservative, debt-free balance sheet. Technicals are moderately supportive with price above key longer-term moving averages and a positive MACD, while valuation is pressured by a negative P/E and no provided dividend yield.
Positive Factors
Debt-Free Balance Sheet
A debt-free structure and substantial equity base reduce financial risk and preserve flexibility through difficult biotech investment cycles. Syncona can therefore support portfolio companies and fund commitments without the added pressure of mandatory debt repayment or significant interest costs.
Negative Factors
Loss-Making and Volatile Results
The shift from profit to losses across the latest reporting periods shows that earnings are not yet dependable. Continued negative EBIT and EBITDA reduce internal capital generation and make future results more sensitive to portfolio outcomes, investment valuations and the timing of exits.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
A debt-free structure and substantial equity base reduce financial risk and preserve flexibility through difficult biotech investment cycles. Syncona can therefore support portfolio companies and fund commitments without the added pressure of mandatory debt repayment or significant interest costs.
Read all positive factors
Syncona Shs GBP (SYNC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£779.70M
Dividend Yield1.01%
Average Volume (3M)2.17M
Price to Earnings (P/E)―
Beta (1Y)0.41
Revenue Growth-40.88%
EPS Growth93.65%
CountryUK
Employees1,226
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)-0.01
Shares Outstanding608,193,050
10 Day Avg. Volume496,621
30 Day Avg. Volume2,172,067
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)0.52
Price to Sales (P/S)9.39
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£189.00Price Target Upside76.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£49.14M
Syncona Shs GBP Business Overview & Revenue Model
Company Description
Syncona Ltd. is a closed-end investment fund, which engages in delivering returns from investments in long and alternative investment funds across multiple asset classes and targets. Its portfolio includes commercial companies, late-stage clinical...
How the Company Makes Money
Syncona makes money primarily through investment returns from its portfolio of life sciences companies rather than through selling products or services itself. Its main economic driver is growth in the fair value of its holdings (unrealised gains)...
Syncona Shs GBP Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
53
Neutral
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 57.34M | -68.31M | 30.75M | -39.79M | 18.69M |
| Gross Profit | 43.36M | -68.31M | 14.10M | -51.91M | 3.68M |
| EBITDA | -8.80M | -143.16M | 8.14M | 0.00 | 11.15M |
| Net Income | -8.80M | -143.16M | 3.79M | -56.02M | 8.84M |
Balance Sheet | |||||
| Total Assets | 1.05B | 1.06B | 1.25B | 1.27B | 1.33B |
| Cash, Cash Equivalents and Short-Term Investments | 1.92M | 1.11M | 261.00K | 11.00K | 276.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 14.95M | 11.79M | 12.22M | 13.76M | 23.55M |
| Stockholders Equity | 1.04B | 1.05B | 1.24B | 1.25B | 1.31B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | 43.91M | 20.47M | -265.00K | 262.00K |
| Operating Cash Flow | 23.33M | 43.91M | 20.47M | -265.00K | 262.00K |
| Investing Cash Flow | -15.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -6.78M | -43.06M | -20.22M | 0.00 | 0.00 |
Syncona Shs GBP Technical Analysis
Positive
107.00
Price Trends
116.58
Positive
110.16
Positive
102.52
Positive
Market Momentum
3.40
Negative
76.31
Negative
64.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SYNC, the sentiment is Positive. The current price of 107 is below the 20-day moving average (MA) of 123.81, below the 50-day MA of 116.58, and above the 200-day MA of 102.52, indicating a bullish trend. The MACD of 3.40 indicates Negative momentum. The RSI at 76.31 is Negative, neither overbought nor oversold. The STOCH value of 64.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SYNC.
Syncona Shs GBP Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £1.50B | 14.03 | 13.19% | 7.43% | 2.50% | 27.89% | |
75 Outperform | £1.93B | 14.76 | 4.51% | 2.03% | 68.95% | 109.67% | |
69 Neutral | £1.14B | 9.82 | 9.21% | ― | -78.12% | 30945.45% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
60 Neutral | £127.94M | -15.02 | -4.78% | 3.28% | -2.25% | -350.00% | |
55 Neutral | £607.80M | 4.52 | 14.25% | 2.09% | -37.29% | ― | |
52 Neutral | £779.70M | -89.03 | -0.86% | 1.01% | -40.88% | 93.65% |
* Financial Sector Average
GB:SYNC
Syncona Shs GBP
128.20
27.80
27.69%
GB:ASHM
Ashmore Group PLC
227.40
54.54
31.55%
GB:GROW
Molten Ventures
667.50
195.50
41.42%
GB:IPO
IP Group plc
70.20
12.20
21.03%
GB:MERC
Mercia Asset Management
30.50
2.11
7.43%
GB:CLDN
Caledonia Investments
377.50
0.26
0.07%
Syncona Shs GBP Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Syncona Boosts OMass Stake as Biotech Raises $310m Series C
Positive
Oct 15, 2026
Syncona has committed $10.1 million to a $310 million oversubscribed Series C financing for portfolio company OMass Therapeutics, a University of Oxford spin-out developing small molecule drugs for rare diseases and immunological conditions. The r...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Syncona Portfolio Firm Beacon Shows Strong Pivotal Data in XLRP Gene Therapy
Positive
Oct 12, 2026
Syncona has highlighted new clinical data from Beacon Therapeutics, a key portfolio company, which presented pivotal Phase II/III results for its gene therapy laru-zova in X-linked retinitis pigmentosa at the American Academy of Ophthalmology meet...
Business Operations and StrategyExecutive/Board Changes
Syncona reshapes leadership to drive value in maturing life sciences portfolio
Positive
Sep 29, 2026
Syncona Investment Management Limited has overhauled its leadership structure to support value creation as its portfolio shifts toward predominantly clinical-stage companies. Chief Executive Chris Hollowood will also serve as Chief Investment Offi...
Business Operations and StrategyProduct-Related Announcements
Syncona’s Beacon Therapeutics hits pivotal XLRP trial milestone, marking key value inflection
Positive
Sep 21, 2026
Syncona said portfolio company Beacon Therapeutics has reported positive topline results from its Phase II/III pivotal VISTA trial of laru-zova, a gene therapy for X-linked retinitis pigmentosa. The study met its FDA-endorsed primary endpoint, sho...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Syncona shareholders approve all resolutions at 2026 AGM
Positive
Aug 18, 2026
Syncona Limited reported that all resolutions presented at its 2026 Annual General Meeting on 18 August were duly passed by shareholders, covering acceptance of the annual financial statements and the re-appointment and remuneration of the company...
Business Operations and StrategyFinancial Disclosures
Syncona Highlights Portfolio Progress and Prepares for Key Value Milestones
Positive
Aug 6, 2026
Syncona reported first-quarter net assets of £1,038.1 million, with its Life Science Portfolio rising to £866.7 million and capital deployment concentrated entirely in late-stage and clinical-stage companies, notably Spur Therapeutics an...
Business Operations and StrategyRegulatory Filings and Compliance
Syncona Updates Total Voting Rights and Share Capital Structure
Neutral
Aug 3, 2026
Syncona Limited has reported that as of 31 July 2026 it has 672,558,750 ordinary shares in issue, of which 64,356,396 are held in treasury and carry no voting rights. This leaves 608,202,354 voting rights in the company, a key figure investors mus...
Business Operations and StrategyRegulatory Filings and Compliance
Syncona Issues New Shares Under Long‑Term Incentive Scheme
Neutral
Jul 23, 2026
Syncona Ltd has announced the issue of 9,330 new ordinary shares, equivalent to about 0.002% of its existing share capital, to satisfy awards under its long‑term incentive scheme. The new shares will rank pari passu with existing ordinary sh...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.